title: Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
abstract: Today, cognitive impairment can be successfully treated with acetylcholine esterase inhibitors (AChE-I) in many, but not all, patients with Alzheimer's disease (AD). To investigate the relation between tacrine treatment, inheritance of ApoE epsilon4 alleles, and rate of progression, the differences in MMSE and CIBIC scores (efficacy parameters) after 6 and 12 months of tacrine (an AChE-I) treatment were investigated in 145 AD patients. Of these, 84 were ApoE epsilon4-positive (ApoE4) and 61 were ApoE epsilon4-negative (ApoE2-3). No differences were found after 6 months of treatment, but after 12 months the CIBIC scores revealed that the ApoE4 patients had declined more than the ApoE2-3 patients (p < 0.05). No differences were found for the last 6 months of treatment. The results primarily suggest a faster rate of decline in the ApoE4 AD compared to the ApoE2-3, but may also reflect that ApoE epsilon4 genotype inheritance is a negative predictor of treatment effect of tacrine in AD patients.
authors.affiliation: Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital/Mölndal, Sweden. magnus.sjogren@medfak.gu.se
authors.forename: M
authors.initials: M
authors.lastname: Sjögren
authors.forename: C
authors.initials: C
authors.lastname: Hesse
authors.forename: H
authors.initials: H
authors.lastname: Basun
authors.forename: G
authors.initials: G
authors.lastname: Köl
authors.forename: H
authors.initials: H
authors.lastname: Thostrup
authors.forename: L
authors.initials: L
authors.lastname: Kilander
authors.forename: J
authors.initials: J
authors.lastname: Marcusson
authors.forename: A
authors.initials: A
authors.lastname: Edman
authors.forename: A
authors.initials: A
authors.lastname: Wallin
authors.forename: I
authors.initials: I
authors.lastname: Karlsson
authors.forename: M
authors.initials: M
authors.lastname: Troell
authors.forename: G
authors.initials: G
authors.lastname: Wachtmaister
authors.forename: A
authors.initials: A
authors.lastname: Ekdahl
authors.forename: H
authors.initials: H
authors.lastname: Olofsson
authors.forename: A
authors.initials: A
authors.lastname: Sandström
authors.forename: N
authors.initials: N
authors.lastname: Andreasen
authors.forename: L
authors.initials: L
authors.lastname: Minthon
authors.forename: K
authors.initials: K
authors.lastname: Blennow
mesh_terms: D000368:Aged; D000483:Alleles; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics*; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D018450:Disease Progression; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000627:therapeutic use*; D011594:Psychometrics; D013619:Tacrine / Q000627:therapeutic use*
chemical_list: D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D013619:Tacrine